NEW YORK, NY / ACCESS Newswire / March 23, 2026 / The global wellness economy is valued at $6.3 trillion and is projected to reach $9 trillion by 2028. Yet, most companies continue competing in ...
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in ...
Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial and operational results on March 14th, 2025. Other corporate achievements ...
IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...
INB.bio today announced the continued expansion of its nutra wellness ecosystem across emerging markets, strengthening its presence in Africa, the Middle East and North Africa (MENA), South Asia, and ...
INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia
The MarketWatch News Department was not involved in the creation of this content. BERLIN, March 22, 2026 (GLOBE NEWSWIRE) -- Global demand for wellness products is climbing steadily, with the industry ...
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp ...
Zacks Small Cap Research on MSN
INAB: Continued Survival in INB-100 Trial
IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February 11 th press release in preparation for ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results